The diagnostic power of CD117, CD13, CD56, CD64, and MPO in rapid screening acute promyelocytic leukemia

The same immuno-phenotype between HLA-DR-negative acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) causes APL rapid screening to become difficult. This study aimed to identify the associated antigens for APL and the best model in clinical uses. A total of 36 APL (PML-RARA+) and 29...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC research notes 2020-08, Vol.13 (1), p.394-394, Article 394
Hauptverfasser: Tran, Vinh Thanh, Phan, Thang Thanh, Mac, Hong-Phuoc, Tran, Tung Thanh, Ho, Toan Trong, Pho, Suong Phuoc, Nguyen, Van-Anh Ngoc, Vo, Truc-My, Nguyen, Hue Thi, Le, Thao Thi, Vo, Tin Huu, Nguyen, Son Truong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The same immuno-phenotype between HLA-DR-negative acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) causes APL rapid screening to become difficult. This study aimed to identify the associated antigens for APL and the best model in clinical uses. A total of 36 APL (PML-RARA+) and 29 HLA-DR-negative non-APL patients enrolled in this study. When a cut-off point of 20% events was applied to define positive or negative status, APL and non-APL patients share a similar immuno-phenotype of CD117, CD34, CD11b, CD13, CD33, and MPO (P > 0.05). However, expression intensity of CD117 (P = 0.002), CD13 (P 
ISSN:1756-0500
1756-0500
DOI:10.1186/s13104-020-05235-7